Skip to main content
. 2019 Jun 19;3(3):pkz042. doi: 10.1093/jncics/pkz042

Figure 3.

Figure 3.

A graphical overview of the evidence for circulating tumor DNA (ctDNA) use in clinical practice. The most promising markers are presented for each clinical implication. Markers considered to be of special interest are underlined. Other markers depicted in the figure are promising but require further research. CNA = copy number alteration.